Several International Market Authorisations Expected in Q4 Expanding Access to South and Central America and Asia
NEW YORK, Sept. 15, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announces initial commercial uptake of Strontium89, its FDA approved drug for the non-opioid treatment of metastatic cancer in the bone.
Please visit http://www.QBioMed.com and sign up for regular updates.